Syndecan-1 expression in locally invasive and metastatic prostate cancer Journal Article


Authors: Chen, D.; Adenekan, B.; Chen, L.; Vaughan, E D.; Gerald, W.; Feng, Z. D.; Knudsen, B. S.
Article Title: Syndecan-1 expression in locally invasive and metastatic prostate cancer
Abstract: Objectives. To determine the significance of syndecan-1 expression, a cell-surface heparan sulfate proteoglycan in localized and metastatic prostate cancer. Methods. We performed a retrospective analysis of 76 men with Gleason sum 6 or 7 prostate cancer treated by radical prostatectomy and a separate cohort of 75 men with metastatic prostate cancer. Syndecan-1 immunoreactivity was measured in primary prostate specimens or in samples from metastatic sites and correlated with patient outcome. Results. Syndecan-1 was expressed in normal basal and secretory epithelial cells, 26% of radical prostatectomy specimens, and 35% of metastatic disease. No association was found between syndecan-1 positivity and prostate-specific antigen recurrence in the collective cohort of Gleason sum 6 and 7 cancers. However, when stratified by Gleason sum, syndecan-1 immunoreactivity (immunoreactivity score 150 or greater) was associated with a greater recurrence rate in Gleason sum 7 cancers. Expression of syndecan-1 was significantly greater in soft tissue than in bone metastasis (P = 0.048, Fisher's exact test). Conclusions. Consistent with a possible biochemical role for synclecan-1 in prostate cancer progression and metastasis, synclecan-1 expression correlated with serologic recurrence in Gleason sum 7 prostate cancer and was highly expressed in soft-tissue metstatases. (C) 2004 Elsevier Inc.
Keywords: progression; carcinoma; radical prostatectomy; receptor; uterine cervix; myeloma; prognostic-significance; association; cell-adhesion; growth-factor-binding
Journal Title: Urology
Volume: 63
Issue: 2
ISSN: 0090-4295
Publisher: Elsevier Science, Inc.  
Date Published: 2004-02-01
Start Page: 402
End Page: 407
Language: English
ACCESSION: WOS:000188995300047
DOI: 10.1016/j.urology.2003.08.036
PROVIDER: wos
PUBMED: 14972511
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. William L Gerald
    375 Gerald